BGM
NTLA icon

Burkehill Global Management’s Intellia Therapeutics NTLA Stock Holding History

Burkehill Global Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846K Buy
+50,000
New +$700K 0.03% 159

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Burkehill Global Management's NTLA Position: Q2 2026 in Review

Burkehill Global Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 50,000 shares worth $846K. The stake represents 0.03% of the portfolio and ranks #159 among its holdings.

328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Burkehill Global Management held 50,000 shares of Intellia Therapeutics worth $846K as of Q2 2026.
  • Intellia Therapeutics was a new Burkehill Global Management position in Q2 2026.
  • Intellia Therapeutics made up 0.03% of Burkehill Global Management's portfolio in Q2 2026, its #159 holding.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.